U.S. flag

An official website of the United States government

NM_000321.3(RB1):c.2042G>A (p.Trp681Ter) AND Retinoblastoma

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Aug 12, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003101027.3

Allele description [Variation Report for NM_000321.3(RB1):c.2042G>A (p.Trp681Ter)]

NM_000321.3(RB1):c.2042G>A (p.Trp681Ter)

Gene:
RB1:RB transcriptional corepressor 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
13q14.2
Genomic location:
Preferred name:
NM_000321.3(RB1):c.2042G>A (p.Trp681Ter)
HGVS:
  • NC_000013.11:g.48459769G>A
  • NG_009009.1:g.161023G>A
  • NM_000321.3:c.2042G>AMANE SELECT
  • NM_001407165.1:c.2042G>A
  • NP_000312.2:p.Trp681Ter
  • NP_000312.2:p.Trp681Ter
  • NP_001394094.1:p.Trp681Ter
  • LRG_517t1:c.2042G>A
  • LRG_517:g.161023G>A
  • LRG_517p1:p.Trp681Ter
  • NC_000013.10:g.49033905G>A
  • NM_000321.2:c.2042G>A
Protein change:
W681*
Molecular consequence:
  • NM_000321.3:c.2042G>A - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001407165.1:c.2042G>A - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Retinoblastoma (RB1)
Synonyms:
Eye cancer, retinoblastoma; RETINOBLASTOMA, SOMATIC
Identifiers:
MONDO: MONDO:0008380; MeSH: D012175; MedGen: C0035335; Orphanet: 790; OMIM: 180200; Human Phenotype Ontology: HP:0009919

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003442227Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Aug 12, 2022)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma.

Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Panton R, Branco P, Gallie B.

Am J Hum Genet. 2003 Feb;72(2):253-69. Epub 2002 Dec 18.

PubMed [citation]
PMID:
12541220
PMCID:
PMC379221

Genotype-phenotype correlations in hereditary familial retinoblastoma.

Taylor M, Dehainault C, Desjardins L, Doz F, Levy C, Sastre X, Couturier J, Stoppa-Lyonnet D, Houdayer C, Gauthier-Villars M.

Hum Mutat. 2007 Mar;28(3):284-93.

PubMed [citation]
PMID:
17096365
See all PubMed Citations (3)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003442227.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with retinoblastoma (PMID: 12541220). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Trp681*) in the RB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RB1 are known to be pathogenic (PMID: 17096365).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024